A Phase II, Randomized, Double-Blind, Multicenter, Parallel Group Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug RO5024048 in Combination With Telaprevir and Pegasys®/Copegus® in Patients With Chronic Hepatitis C Genotype 1 Virus Infection Who Were Prior Null Responders to Treatment With Pegylated Interferon/Ribavirin
Latest Information Update: 14 Jan 2020
Price :
$35 *
At a glance
- Drugs Mericitabine (Primary) ; Peginterferon alfa-2a; Ribavirin; Telaprevir
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms Dynamo 2
- Sponsors Genentech; Roche
- 13 Apr 2014 Results presented at the 49th Annual Meeting of the European Association for the Study of the Liver.
- 24 Feb 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 13 Dec 2013 Planned End Date changed from 1 Feb 2014 to 1 Jan 2014; as reported by ClinicalTrials.gov.